Precision Cancer Therapy in Rare Cancers (MATRIX-Rare)

University of Oslo (UIO)

Status and phase: Enrolling; Phase 2

Conditions: Rare Malignant Neoplasm

Treatments: Drug: Trametinib; Drug: Imatinib; Drug: Dabrafenib

Study type: Interventional

Funder types: Other

Identifiers

NCT06119789

MATRIX-Rare

Details and patient eligibility

About

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.

In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Full description

All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor cells.

Enrollment: 96 estimated patients

Sex: All

Ages: 16 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ECOG 0-2,
• identified biomarker,
• reasonable biochemistry

Exclusion criteria

• ECOG 3-5
• serious other diseases

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

96 participants in 1 patient group

treatment according to genetic alterations

Experimental group

Description:

treatment according to genetic alterations

Treatment:

Drug: Dabrafenib

Drug: Trametinib

Drug: Imatinib